As an ideal research hotspot, an increasing number of neoadjuvant trials are under investigation to explore the combination of HER2‐targeted therapy and endocrine therapy in patients with HR‐positive, HER2‐positive breast cancer. Here, ERBB2 is linked to breast carcinoma.